image
Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 109.52
-5.63 %
$ 13.3 B
Market Cap
52.4
P/E
1. INTRINSIC VALUE

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries.[ Read More ]

The intrinsic value of one RVTY stock under the base case scenario is HIDDEN Compared to the current market price of 110 USD, Revvity, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RVTY

image
FINANCIALS
2.75 B REVENUE
-16.95%
301 M OPERATING INCOME
-59.53%
180 M NET INCOME
-69.01%
91.3 M OPERATING CASH FLOW
-86.57%
1.31 B INVESTING CASH FLOW
1088.72%
-947 M FINANCING CASH FLOW
-43.11%
684 M REVENUE
-1.10%
98.2 M OPERATING INCOME
-3.32%
-688 M NET INCOME
-947.83%
148 M OPERATING CASH FLOW
-6.77%
690 M INVESTING CASH FLOW
468.09%
-874 M FINANCING CASH FLOW
-3197.74%
Balance Sheet Decomposition Revvity, Inc.
image
Current Assets 3 B
Cash & Short-Term Investments 1.6 B
Receivables 633 M
Other Current Assets 765 M
Non-Current Assets 10.6 B
Long-Term Investments 82.8 M
PP&E 665 M
Other Non-Current Assets 9.82 B
Current Liabilities 1.45 B
Accounts Payable 204 M
Short-Term Debt 755 M
Other Current Liabilities 492 M
Non-Current Liabilities 4.24 B
Long-Term Debt 3.31 B
Other Non-Current Liabilities 931 M
EFFICIENCY
Earnings Waterfall Revvity, Inc.
image
Revenue 2.75 B
Cost Of Revenue 1.58 B
Gross Profit 1.17 B
Operating Expenses 874 M
Operating Income 301 M
Other Expenses 121 M
Net Income 180 M
RATIOS
42.70% GROSS MARGIN
42.70%
10.93% OPERATING MARGIN
10.93%
25.20% NET MARGIN
25.20%
8.80% ROE
8.80%
5.11% ROA
5.11%
2.50% ROIC
2.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Revvity, Inc.
image
Net Income 180 M
Depreciation & Amortization 432 M
Capital Expenditures -81.4 M
Stock-Based Compensation 41.4 M
Change in Working Capital -391 M
Others -338 M
Free Cash Flow 9.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Revvity, Inc.
image
Wall Street analysts predict an average 1-year price target for RVTY of $127 , with forecasts ranging from a low of $110 to a high of $140 .
RVTY Lowest Price Target Wall Street Target
110 USD 0.44%
RVTY Average Price Target Wall Street Target
127 USD 15.85%
RVTY Highest Price Target Wall Street Target
140 USD 27.83%
4. DIVIDEND ANALYSIS
0.06% DIVIDEND YIELD
0.07 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Revvity, Inc.
image
Sold
0-3 MONTHS
789 K USD 1
3-6 MONTHS
955 K USD 2
6-9 MONTHS
1.59 M USD 4
9-12 MONTHS
3.83 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Oct 09, 2024
Sell 260 K USD
Vohra Tajinder S
Please See Remarks
- 2134
121.72 USD
1 month ago
Oct 09, 2024
Sell 2.45 K USD
Vohra Tajinder S
Please See Remarks
- 20
122.56 USD
1 month ago
Oct 07, 2024
Sell 251 K USD
Vohra Tajinder S
Please See Remarks
- 2053
122.04 USD
1 month ago
Oct 07, 2024
Sell 12.3 K USD
Vohra Tajinder S
Please See Remarks
- 100
123.05 USD
1 month ago
Oct 08, 2024
Sell 203 K USD
Vohra Tajinder S
Please See Remarks
- 1661
122.47 USD
1 month ago
Oct 08, 2024
Sell 60.6 K USD
Vohra Tajinder S
Please See Remarks
- 493
122.99 USD
3 months ago
Aug 15, 2024
Sell 101 K USD
MICHAS ALEXIS P
Director
- 850
118.62 USD
3 months ago
Aug 07, 2024
Sell 112 K USD
Goldberg Joel S
Please See Remarks
- 964
116.06 USD
3 months ago
Aug 07, 2024
Sell 82.2 K USD
Goldberg Joel S
Please See Remarks
- 703
116.86 USD
3 months ago
Aug 07, 2024
Sell 93.3 K USD
Goldberg Joel S
Please See Remarks
- 785
118.8 USD
3 months ago
Aug 07, 2024
Sell 125 K USD
Goldberg Joel S
Please See Remarks
- 1048
119.48 USD
5 months ago
Jun 07, 2024
Sell 312 K USD
Goldberg Joel S
Please See Remarks
- 2824
110.32 USD
5 months ago
Jun 07, 2024
Sell 130 K USD
Goldberg Joel S
Please See Remarks
- 1176
110.8 USD
8 months ago
Feb 29, 2024
Sell 550 K USD
MICHAS ALEXIS P
Director
- 5000
109.98 USD
8 months ago
Feb 27, 2024
Sell 278 K USD
Vohra Tajinder S
Please See Remarks
- 2652
104.84 USD
8 months ago
Feb 27, 2024
Sell 556 K USD
Vohra Tajinder S
Please See Remarks
- 5266
105.66 USD
8 months ago
Feb 23, 2024
Sell 87.8 K USD
Goldberg Joel S
Please See Remarks
- 835
105.13 USD
8 months ago
Feb 23, 2024
Sell 120 K USD
Singh Prahlad R.
Please See Remarks
- 1144
105.13 USD
9 months ago
Feb 05, 2024
Sell 1.53 M USD
Singh Prahlad R.
Please See Remarks
- 14749
104.05 USD
9 months ago
Feb 05, 2024
Sell 678 K USD
Singh Prahlad R.
Please See Remarks
- 6468
104.8 USD
9 months ago
Feb 05, 2024
Sell 1.2 M USD
Goldberg Joel S
Please See Remarks
- 11546
104.08 USD
9 months ago
Feb 05, 2024
Sell 384 K USD
Goldberg Joel S
Please See Remarks
- 3662
104.8 USD
9 months ago
Feb 05, 2024
Sell 28.2 K USD
Goldberg Joel S
Please See Remarks
- 267
105.66 USD
7. News
These Analysts Revise Their Forecasts On Revvity Following Q3 Results Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday. benzinga.com - 1 week ago
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales. zacks.com - 1 week ago
Revitty (RVTY) Q3 2024 Earnings Call Transcript Revitty Incorporated (NYSE:RVTY ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Prahlad Singh - President, Chief Executive Officer Max Krakowiak - Senior Vice President, Chief Financial Officer Steve Willoughby - Head of Investor Relations Conference Call Participants Mike Ryskin - Bank of America Vijay Kumar - Evercore ISI Dan Leonard - UBS Andrew Cooper - Raymond James Luke Sergott - Barclays Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Dan Arias - Stifel Matt Sykes - Goldman Sachs Brandon Couillard - Wells Fargo Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Hello everyone and welcome to Revitty's third quarter 2024 earnings conference call. My name is Lydia and I will be your Operator today. seekingalpha.com - 1 week ago
Here's What Key Metrics Tell Us About Revvity (RVTY) Q3 Earnings Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 week ago
Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago. zacks.com - 1 week ago
Revvity cuts 2024 revenue forecast amid biotech spending slowdown Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development. reuters.com - 1 week ago
Revvity Announces Financial Results for the Third Quarter of 2024 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024. The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $98 million, as compared to $69 million for the same period a year ago. GAA. businesswire.com - 1 week ago
Revvity to Report Q3 Earnings: What's in Store for the Stock? RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China. zacks.com - 2 weeks ago
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Revvity Board Declares Quarterly Dividend WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fro. businesswire.com - 3 weeks ago
Revvity Shares Decline Despite Launch of Transcribe AI Solution RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors. zacks.com - 3 weeks ago
Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company's sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity's continued evolution and strengthened commitments to creating a lasting, positive impact on the world. “Whether it's from developing groundbreaking solutions that drive positive health outcomes or through our sustainability initiatives, such as reducing waste a. businesswire.com - 3 weeks ago
8. Profile Summary

Revvity, Inc. RVTY

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 13.3 B
Dividend Yield 0.06%
Description Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Contact 940 Winter Street, Waltham, MA, 02451 https://www.perkinelmer.com
IPO Date July 6, 1965
Employees 11000
Officers Dr. Prahlad R. Singh Ph.D. Chief Executive Officer, President & Director Ms. Magali Four Senior Vice President and Chief People & Culture Officer Mr. Maxwell Krakowiak Senior Vice President & Chief Financial Officer Mr. Joel S. Goldberg Senior Vice President of Administration, General Counsel & Secretary Mr. Tajinder S. Vohra Senior Vice President of Global Operations Mr. Andrew Okun Vice President, Chief Accounting Officer & Treasurer Ms. Miriame Victor Senior Vice President & Chief Commercial Officer Ms. Madhuri Hegde FACMG, Ph.D. Senior Vice President & Chief Scientific Officer Mr. Bryan A. Kipp Senior Vice President of Technology & Licensing Mr. Stephen Barr Willoughby Senior Vice President of Investor Relations & Head of ESG